Literature DB >> 20306031

Alpha particles more promising than toxins?

Jacques Barbet, Michel Chérel, Jean-François Chatal.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20306031     DOI： 10.1007/s00259-010-1421-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  11 in total

Review 1.  Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.

Authors:  M R Zalutsky; D D Bigner
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

2.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

Authors:  R W Kozak; R W Atcher; O A Gansow; A M Friedman; J J Hines; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

3.  Investigators review potential of antibodies in cancer detection and therapy.

Authors:  S C Srivastava
Journal:  J Nucl Med       Date:  1987-02       Impact factor: 10.057

4.  Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.

Authors:  Torsten Liersch; Johannes Meller; Bettina Kulle; Thomas M Behr; Peter Markus; Claus Langer; B Michael Ghadimi; William A Wegener; Jacqueline Kovacs; Ivan D Horak; Heinz Becker; David M Goldenberg
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

Review 5.  Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Authors:  Roberto Stasi
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

Review 6.  Antibody-drug conjugates for cancer therapy.

Authors:  Paul J Carter; Peter D Senter
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360

7.  The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.

Authors:  Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Robert J Lutz; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Sonia Vallet; Samantha Pozzi; Loredana Santo; Giulia Perrone; Yu-Tzu Tai; Diana Cirstea; Noopur S Raje; Christoph Uherek; Benjamin Dälken; Silke Aigner; Frank Osterroth; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen.

Authors:  D M Goldenberg; S A Gaffar; S J Bennett; J L Beach
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.

Authors:  H E Blythman; P Casellas; O Gros; P Gros; F K Jansen; F Paolucci; B Pau; H Vidal
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

10.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Authors:  Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 13.312
View more
  2 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Challenges in nuclear medicine: innovative theranostic tools for personalized medicine.

Authors:  Françoise Kraeber-Bodéré; Jacques Barbet
Journal:  Front Med (Lausanne)       Date:  2014-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.